ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.

Related Keywords

Houston ,Texas ,United States ,Genentech Roche ,Morphosys Incyte ,Jason Westin ,Lymphoma Clinical Research Program ,Janssen Scientific Affairs ,Genentech ,Novartis ,Astrazeneca ,Bristol Myers Squibb ,Department Of Lymphoma ,University Of Texas Md Anderson Cancer Center ,New England Journal ,Aggressive Lymphoma ,Cancer Center ,Bristol Myers ,Iksuda Therapeutics ,Monte Rosa Therapeutics ,Axi Cel ,Axicabtagene Ciloleucel ,Cart Cell Therapy ,Dlbcl ,Largeb Cell Lymphoma ,Lymphoma ,Zuma 7 Trial ,Pasco ,Asco Annual Meeting ,New England Journal Of Medicine ,D ,The University Of Texas Md Anderson Cancer Center ,Md Anderson ,